40.91
+1.55(+3.94%)
Currency In USD
| Previous Close | 39.36 |
| Open | 39.11 |
| Day High | 41.22 |
| Day Low | 38 |
| 52-Week High | 41.22 |
| 52-Week Low | 16.54 |
| Volume | 625,405 |
| Average Volume | 384,108 |
| Market Cap | 1.17B |
| PE | -25.1 |
| EPS | -1.63 |
| Moving Average 50 Days | 31.72 |
| Moving Average 200 Days | 28.55 |
| Change | 1.55 |
If you invested $1000 in LENZ Therapeutics, Inc. (LENZ) since IPO date, it would be worth $2,525.31 as of August 14, 2025 at a share price of $40.91. Whereas If you bought $1000 worth of LENZ Therapeutics, Inc. (LENZ) shares 6 months ago, it would be worth $1,622.13 as of August 14, 2025 at a share price of $40.91.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia
GlobeNewswire Inc.
Jul 31, 2025 8:05 PM GMT
VIZZ is the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia, a condition impacting approximately 128 million adults in the United States First once daily solution to treat blurry near vision with pro
LENZ Therapeutics Announces NMPA Submission of New Drug Application for LNZ100 in China for the Treatment of Presbyopia
GlobeNewswire Inc.
Jul 28, 2025 12:00 PM GMT
Submission of NDA for LNZ100 in China by CORXEL Pharmaceuticals results in achievement of first milestone due to LENZ under the Development and Commercialization Agreement SAN DIEGO, July 28, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq
LENZ Therapeutics and Laboratoires Théa Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada
GlobeNewswire Inc.
Jul 07, 2025 12:00 PM GMT
Exclusive agreement includes over $70 million in upfront and milestone payments to LENZ in addition to double-digit royalties on net salesSAN DIEGO and CLERMONT-FERRAND, France, July 07, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LEN